SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 15.64 |
Enterprise Value ($M) | 8.39 |
Book Value ($M) | 12.04 |
Book Value / Share | 3.19 |
Price / Book | 1.30 |
NCAV ($M) | 5.25 |
NCAV / Share | 1.39 |
Price / NCAV | 2.98 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.91 |
Return on Assets (ROA) | -2.83 |
Return on Equity (ROE) | -4.83 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.55 |
Current Ratio | 2.55 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 12.66 |
Assets | 14.86 |
Liabilities | 7.41 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -15.64 |
Net Income | -15.55 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -18.45 |
Cash from Investing | -0.21 |
Cash from Financing | 30.82 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Lind Global Fund II LP | 3.10 | -64.92 | |
13D/A | Werth Peter J. | 4.51 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
21,888 | 61,014 | 35.87 | |
8,945 | 41,682 | 21.46 | |
49,559 | 133,901 | 37.01 | |
4,554 | 37,162 | 12.25 | |
(click for more detail) |
Similar Companies | |
---|---|
CELZ – Creative Medical Technology Holdings, Inc. | CGEN – Compugen Ltd. |
CGTX – Cognition Therapeutics, Inc. | CKPT – Checkpoint Therapeutics, Inc. |
CLDX – Celldex Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io